Molecular biologist @UMNews, Hormel Institute studying #lungcancer & vascular biology. Associate Professor, Husband, Father of 4, Runner, @MLB fan.
Minnesota, USA
Joined June 2016
- Tweets1K
- Following2.1K
- Followers751
- Likes6.7K
Pinned Tweet
Excited to share our new work revealing the role of IKKα in lung cancer progression in @Nature_NPJ Precision Oncology! Outstanding teamwork by our group! @UMNResearch @UMNCancer #OpenAccess nature.com/articles/s41698-0…
Luke Hoeppner retweeted
BREAKING: Rep. Thomas Massie has joined 26 other elected officials and 45 candidates in publicly stating the COVID shots must be pulled off the market.
Flow cytometry...
How!?
Readers added context they thought people might want to know
This video was made using visual effects. Peg boards cannot sort marbles by color, and similar videos have been circulating for years. This video explains how one was created:
youtube.com/watch?v=em-pVI…
IKKα ablation in human lung adenocarcinoma cells reduced their anchorage-independent growth in soft agar. Mice challenged with IKKα-ablated HCC827 cells exhibited less lung tumor growth than mice orthotopically administered control HCC827 cells.
Inexpensive fluorescence imaging of #zebrafish for classroom and science outreach settings.
Final version of our glowscope project is now out at go.nature.com/3mD7j4S
The paper adds inexpensive fluorescence capability to the wonderful smartphone scopes that @ScopesWorkshop developed and tirelessly brings into classrooms and science outreach settings.
Accepted for publication today! More soon! Excellent work, team!
Our newest preprint is out! We found that IKKalpha directly phosphorylates DARPP-32 to inhibit protein phosphatase 1 (PP1) leading to activation of ERK signaling in #lungcancer.
Luke Hoeppner retweeted
Things I didn’t know before I was diagnosed w Stage IV #lungcancer in Nov 2022
1. For many (like me) 1st symptom was persistent cough. When that’s case, initial tumor has likely spread.
2. To qualify for CT lung cancer screening, you had to smoke a pack a day for 20 yrs.
Currently looking to hire a postdoc. Please reach out &/or apply.
We use cellular function studies, biochemistry, molecular assays, mouse & zebrafish models, & human specimens to study the molecular basis of human disease including cancer, cardiovascular disease, & lung injury.
Luke Hoeppner retweeted
JAK-STAT inhibition reduces endothelial pro-thrombotic activation and leukocyte- endothelial pro-adhesive interactions
Joan D Beckman, Angelica DaSilva, Elena Aronovich,..., Gregory M Vercellotti, Brian Betts, David K Wood
pubmed.ncbi.nlm.nih.gov/3673…
Plunging for Pink this past weekend! Thanks so much to all for your support of #cancer #research! @GradiloneSergio @Plunging4Pink @UMNResearch @UMNCancer @UMNews #HormelInstitute
Postdoc position available in my lab using molecular biology, #zebrafish, mice, & human specimens to study vascular permeability and #lungcancer, including @lcrf_org @EGFRResisters funded studies of EGFR TKI resistance mechanisms.
Please share & contact me if interested. Thanks!
Luke Hoeppner retweeted
Great news: Funding bill has been approved by the senate. Here is what's in it:
NIH: $47.5 billion (+5.1%)
NSF: $9.87 billion (+11.7%)
NASA Science: $7.8 billion (+2.4%)
DOE’s Office of Science: $8.1 billion (+8.4%)
ARPA-H: $1.5 billion
Yeah!
Honored & incredibly grateful to receive a @lcrf_org @EGFRResisters grant to investigate predictive biomarkers & new therapeutic strategies to prevent EGFR TKI-refractory #lungcancer progression! Thrilled to move forward w/ this project! @UMNresearch @UMNCancer #LCSM
Announcing the 2022 class of awardees for LCRF's 2022 Scientific Grant Program! Thanks to generous support from donors and fundraisers, LCRF awarded 15 #LungCancer investigators $2.45M in grants – the largest single-year research investment in its history: lcrf.org/2022grantannounceme…
@politikaterina, thanks so much for calling to share this exciting news! I admire your impactful research & your dedication, including serving as Chair of the LCRF Scientific Advisory Board.
